Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.

Bachy E, Savage KJ, Huang H, Kwong YL, Gritti G, Zhang Q, Liberati AM, Cao J, Yang H, Hao S, Hu J, Zhou K, Petrini M, Russo F, Zhang H, Sang W, Ji J, Ferreri AJM, Damaj GL, Liu H, Zhang W, Ke X, Ghiggi C, Huang S, Li X, Yao H, Paik J, Novotny W, Zhou W, Zhu H, Zinzani PL

Open source

DOI: 10.1182/bloodadvances.2022009575
Published: 2023 Aug 22
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2022009575,
  title = {Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.},
  author = {Bachy E and Savage KJ and Huang H and Kwong YL and Gritti G and Zhang Q and Liberati AM and Cao J and Yang H and Hao S and Hu J and Zhou K and Petrini M and Russo F and Zhang H and Sang W and Ji J and Ferreri AJM and Damaj GL and Liu H and Zhang W and Ke X and Ghiggi C and Huang S and Li X and Yao H and Paik J and Novotny W and Zhou W and Zhu H and Zinzani PL},
  year = {2023},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2022009575},
  url = {https://doi.org/10.1182/bloodadvances.2022009575}
}

RIS

TY  - JOUR
TI  - Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.
AU  - Bachy E
AU  - Savage KJ
AU  - Huang H
AU  - Kwong YL
AU  - Gritti G
AU  - Zhang Q
AU  - Liberati AM
AU  - Cao J
AU  - Yang H
AU  - Hao S
AU  - Hu J
AU  - Zhou K
AU  - Petrini M
AU  - Russo F
AU  - Zhang H
AU  - Sang W
AU  - Ji J
AU  - Ferreri AJM
AU  - Damaj GL
AU  - Liu H
AU  - Zhang W
AU  - Ke X
AU  - Ghiggi C
AU  - Huang S
AU  - Li X
AU  - Yao H
AU  - Paik J
AU  - Novotny W
AU  - Zhou W
AU  - Zhu H
AU  - Zinzani PL
PY  - 2023
JO  - Blood advances
DO  - 10.1182/bloodadvances.2022009575
UR  - https://doi.org/10.1182/bloodadvances.2022009575
ER  -

APA

E, B., KJ, S., H, H., YL, K., G, G., Q, Z., AM, L., J, C., H, Y., S, H., J, H., K, Z., M, P., F, R., H, Z., W, S., J, J., AJM, F., GL, D., H, L., W, Z., X, K., C, G., S, H., X, L., H, Y., J, P., W, N., W, Z., H, Z., & PL, Z. (2023). Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.. Blood advances. https://doi.org/10.1182/bloodadvances.2022009575

Source records

pubmed · retrieved 2026-09-26T13:16:43.300Z